Billions of dollars at stake: MIT and UC-Berkeley  squabble over gene editing technology trademark rights

Genetic engineering and gene editing is predicted to be the next big thing to  happen in the medical field of endeavor.  This is not a mere prediction anymore but has become a reality. Gene editing used to be regarded as impossible and reckoned to be more of a science fiction, but that has since dramatically changed.  At present the UC Berkeley (University of California), Berkeley and the MIT (Massachusetts Institute of Technology) are in a dispute against  each other for the rights to gene editing technology, informed sources said.

Gene editing also known as CRISPR-Cas9, scientists are saying, can break the limitations of modern day medicine.  With the MIT and UC Berkeley locking horns over the rights to this technology, the debate has escalated to an international level.

But,  UC Berkeley and MIT are not the only universities that are in the running over the patent rights of the novel gene editing technology.

The judges, represented by the U.S. Patent and Trademark Office, have awarded the patent rights for the gene technology to the Broad Institute of Harvard and MIT.

However, The UC Berkely did not receive the decision well and therefore  asked the US Patent and Trademark Office to re-assess the decision.

At the moment,  the research team headed by Jenifer Doudna is regarded as the agent for the patent rights of the new gene editing technology.

Though, it appears now that the decision the authorities have come up regarding the patent rights for the new gene editing technology will be questioned again.




Leave a Reply

Your email address will not be published. Required fields are marked *